skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial

Abstract

Purpose: To test whether the angiotensin-converting enzyme inhibitor captopril was effective in mitigating chronic renal failure after hematopoietic stem cell transplantation (HSCT). Methods and Materials: A total of 55 subjects undergoing total body irradiation (TBI)-HSCT were enrolled in this randomized controlled trial. Captopril or identical placebo was started at engraftment and continued as tolerated until 1 year after HSCT. Results: The baseline serum creatinine and calculated glomerular filtration rate (GFR) did not differ between groups. The 1-year serum creatinine level was lower and the GFR higher in the captopril compared with the placebo group (p = 0.07 for GFR). Patient survival was higher in the captopril compared with the placebo group, but this was also not statistically significant (p = 0.09). In study subjects who received the study drug for more than 2 months, the 1-year calculated GFRs were 92 mL/min and 80 mL/min, for the captopril and placebo groups, respectively (p = 0.1). There was no adverse effect on hematologic outcome. Conclusions: There is a trend in favor of captopril in mitigation of chronic renal failure after radiation-based HSCT.

Authors:
 [1];  [2];  [3];  [2];  [4];  [2];  [1]
  1. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI (United States)
  2. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI (United States)
  3. Department of Population Health, Medical College of Wisconsin, Milwaukee, WI (United States)
  4. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI (United States)
Publication Date:
OSTI Identifier:
21124166
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 70; Journal Issue: 5; Other Information: DOI: 10.1016/j.ijrobp.2007.08.041; PII: S0360-3016(07)03992-2; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANGIOTENSIN; CREATININE; ENZYME INHIBITORS; FAILURES; KIDNEYS; STEM CELLS; WHOLE-BODY IRRADIATION

Citation Formats

Cohen, Eric P., Irving, Amy A. B.A., Drobyski, William R, Klein, John P, Passweg, Jakob, Talano, Julie-An M, Juckett, Mark B, and Moulder, John E. Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial. United States: N. p., 2008. Web. doi:10.1016/j.ijrobp.2007.08.041.
Cohen, Eric P., Irving, Amy A. B.A., Drobyski, William R, Klein, John P, Passweg, Jakob, Talano, Julie-An M, Juckett, Mark B, & Moulder, John E. Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial. United States. https://doi.org/10.1016/j.ijrobp.2007.08.041
Cohen, Eric P., Irving, Amy A. B.A., Drobyski, William R, Klein, John P, Passweg, Jakob, Talano, Julie-An M, Juckett, Mark B, and Moulder, John E. 2008. "Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial". United States. https://doi.org/10.1016/j.ijrobp.2007.08.041.
@article{osti_21124166,
title = {Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial},
author = {Cohen, Eric P. and Irving, Amy A. B.A. and Drobyski, William R and Klein, John P and Passweg, Jakob and Talano, Julie-An M and Juckett, Mark B and Moulder, John E},
abstractNote = {Purpose: To test whether the angiotensin-converting enzyme inhibitor captopril was effective in mitigating chronic renal failure after hematopoietic stem cell transplantation (HSCT). Methods and Materials: A total of 55 subjects undergoing total body irradiation (TBI)-HSCT were enrolled in this randomized controlled trial. Captopril or identical placebo was started at engraftment and continued as tolerated until 1 year after HSCT. Results: The baseline serum creatinine and calculated glomerular filtration rate (GFR) did not differ between groups. The 1-year serum creatinine level was lower and the GFR higher in the captopril compared with the placebo group (p = 0.07 for GFR). Patient survival was higher in the captopril compared with the placebo group, but this was also not statistically significant (p = 0.09). In study subjects who received the study drug for more than 2 months, the 1-year calculated GFRs were 92 mL/min and 80 mL/min, for the captopril and placebo groups, respectively (p = 0.1). There was no adverse effect on hematologic outcome. Conclusions: There is a trend in favor of captopril in mitigation of chronic renal failure after radiation-based HSCT.},
doi = {10.1016/j.ijrobp.2007.08.041},
url = {https://www.osti.gov/biblio/21124166}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 5,
volume = 70,
place = {United States},
year = {Tue Apr 01 00:00:00 EDT 2008},
month = {Tue Apr 01 00:00:00 EDT 2008}
}